People with cancer had a nearly twofold increased likelihood of dying within 30 days of a COVID-19 diagnosis and those with worsening cancer had a fivefold increased mortality risk, compared with those without cancer, while those with cancer and COVID-19 who received both azithromycin and hydroxychloroquine had a nearly threefold higher odds of mortality, compared with insignificant death risk among those who were given either drug alone, according to a study presented at the American Society of Clinical Oncology's annual meeting and published in The Lancet. Another study presented at the ASCO annual meeting correlated chemotherapy with or without other therapies within three months of a COVID-19 diagnosis with 64% higher mortality risk among patients with thoracic cancers.
Cancer, chemo tied to higher COVID-19 mortality risk
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.